Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today reported financial results for ...
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by ...